Effects of Statin Medications on Mental Processes, Behavior, and Serotonin Levels

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

1000 participants

Study Classification

INTERVENTIONAL

Study Start Date

2000-04-30

Study Completion Date

2004-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Statins are cholesterol-lowering medications that are often prescribed for individuals with high cholesterol and who are at risk for heart disease. Preliminary research has shown that statins may have other effects on the body that are unrelated to the heart. The purpose of this study is to evaluate the impact of statins on mood, mental processes, aggression, and serotonin levels.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Citalopram on Hostility and CHD Risk

NCT00217828

Cardiovascular Diseases Heart Diseases

COMPLETED NA

Simvastatin and Emotional Processing (OxSTEP)

NCT04973800

Depression Inflammation

COMPLETED NA

The Metabolic Effects of Antidepressants in Patients Diagnosed With Major Depressive Disorder

NCT01418638

Major Depressive Disorder

UNKNOWN

Repetitive Behavior Disorders in People With Severe Mental Retardation

NCT00491478

Mental Retardation Stereotyped Behavior Self-Injurious Behavior +1 more

UNKNOWN PHASE3

Sertraline vs. Placebo for Symptoms Following Traumatic Brain Injury

NCT00208585

Traumatic Brain Injury

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Individuals at risk for coronary artery disease are often prescribed statins, which are medications that reduce the amount of cholesterol in the blood. By lowering cholesterol levels, these individuals have a lower incidence of heart disease, heart attacks, and stroke. Simvastatin and pravastatin are two common statins that are often prescribed for individuals with high cholesterol. While statins are effective at lowering cholesterol levels, their effect on mood, behavior, and aggression has not been widely studied. Preliminary research has shown that lowering cholesterol levels may lead to an increase in aggressive behaviors and a change in cognitive function. Serotonin, a type of neurotransmitter, is believed to play an important role in the regulation of mood, as well as behavior and cognition. The direct effect of statins on serotonin levels remains unknown. The purpose of this study is to evaluate the effect of simvastatin and pravastatin on mood, cognition, aggression, and serotonin levels.

This study will enroll individuals who do not currently take cholesterol-lowering medications. Participants will be randomly assigned to receive 20 mg of simvastatin, 40 mg of pravastatin, or placebo for 6 months. Study visits will occur at baseline and Months 1, 3, 6, and 8. Height, weight, and waist circumference will be measured at all study visits. Blood and urine will be collected for laboratory testing, and standardized psychological questionnaires will assess cognition, aggression, mental flexibility, memory, depression, sleep quality, and quality of life at Months 1, 6, and 8. At Month 3, medication side effects will be monitored and a liver function test will be performed. Participants' partners will take part in a telephone interview at this time. At baseline and Month 6, some participants will undergo cardiac reactivity testing. During this procedure, participants will be videotaped and monitored for vital sign changes (blood pressure and heart rate) while they talk about potentially stressful situations.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dyslipidemias

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Participants will receive 20 mg of simvastatin for 6 months.

Group Type EXPERIMENTAL

20 mg Simvastatin

Intervention Type DRUG

Participants will receive 20 mg of simvastatin for 6 months.

2

Participants will receive 40 mg of pravastatin for 6 months.

Group Type EXPERIMENTAL

40 mg Pravastatin (Pravachol)

Intervention Type DRUG

Participants will receive 40 mg of pravastatin for 6 months.

3

Participants will receive placebo for 6 months.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Participants will receive placebo for 6 months.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

40 mg Pravastatin (Pravachol)

Participants will receive 40 mg of pravastatin for 6 months.

Intervention Type DRUG

20 mg Simvastatin

Participants will receive 20 mg of simvastatin for 6 months.

Intervention Type DRUG

Placebo

Participants will receive placebo for 6 months.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* LDL cholesterol level between 115-190 mg/dL
* Able to fast prior to blood draw
* Able to comfortably read and write in English
* Able and willing to refrain from donating whole blood during study participation
* Willing to abstain from consuming large amounts of grapefruit juice

Exclusion Criteria

* Current use of lipid-lowering medications
* Symptomatic atherosclerotic disease, such as coronary artery disease, kidney failure or insufficiency, peripheral arterial disease, or cerebrovascular disease
* Cancer
* HIV infected
* Medical or psychiatric condition that prevents full study participation or follow-up (e.g., active psychosis)
* Active liver disease or unexplained persistent elevated transaminase levels
* Major surgery or hospitalization in the 3 months prior to study entry
* Current use of cyclosporin, erythromycin, clarithromycin, nefazodone, or any "azole" antifungals, including fluconazole, itraconazole, ketoconazole, mibefradil, or protease inhibitors
* Female of childbearing potential
* Current participation in another clinical trial

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes